NCT07702032
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07702032
Title Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
Acronym LiGeR-CRC1
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Genmab
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Genesis Cancer Center RECRUITING Hot Springs Arkansas 71913 United States Details
Valkyrie Clinical Trials - Los Angeles RECRUITING Los Angeles California 90067 United States Details
Low Country Cancer Care Associates_Savannah_1 RECRUITING Savannah Georgia 31405 United States Details
Central Georgia Cancer Care - Warner Robins Office RECRUITING Warner Robins Georgia 31088 United States Details
Hematology-Oncology of Indiana, P.C. RECRUITING Indianapolis Indiana 46260 United States Details
Oncology Hematology Associates - Springfield_Springfield_2 RECRUITING Springfield Missouri 65807 United States Details
Vista Oncology RECRUITING Olympia Washington 98502 United States Details
PanOncology RECRUITING Manati PR 00674 Puerto Rico Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field